The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: A meta-analysis

Xue, Ren-Liang; Cai, Xiumei; Xu, Hanbing; Wu, Sihan; Huang, Huaiyi

doi:10.1016/j.ygyno.2018.07.005

Cited by 21 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 A recent metaanalysis of 12 studies (1,698 patients) suggested poorer tumor response and a trend toward inferior survival with substitution of weekly carboplatin for cisplatin. 29 The phase III randomized trial, tri-weekly cisplatin-based chemoradiation for locally advanced cervical cancer (TACO) (ClinicalTrials.gov identifier: NCT01561586), is studying the proposed benefits conferred by three times per week cisplatin (75 mg/m 2 ), which includes increased peak concentration and administration during brachytherapy. 30 Neoadjuvant chemotherapy has been proposed to improve disease control and reduce toxicity.…”

Section: Point Pmentioning

confidence: 99%

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma

Tewari

Monk

2019

JCO

View full text Add to dashboard Cite

Section: Point Pmentioning

confidence: 99%

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma

Tewari

Monk

2019

JCO

View full text Add to dashboard Cite

“…Based on both randomized and retrospective trials, weekly DDP administration has been recommended due to similar survival rates versus other regimens but with fewer side-effects [23–25]. Although carboplatin (weekly; AUC 2) is recommended in patients who cannot be administered DDP, survival rates and tumor responses are lower than for DDP [26]. In our study, concurrent chemotherapeutic agent was DDP and administered 40 mg per square meter once a week to all patients, as recommended.…”

Section: Discussionmentioning

confidence: 99%

Radical radiotherapy in patients with cervix uteri carcinoma: experience of Ondokuz Mayis University

et al. 2019

View full text Add to dashboard Cite

BackgroundRadical radiotherapy is the standard treatment for patients with locally advanced cervix uteri carcinoma (FIGO stage IB2–IVA). Worldwide, incidence and mortality rates vary among regions because of differences in lifestyles and treatment standards. Herein, we evaluated the outcomes of radical radiotherapy in patients with locally advanced cervix uteri carcinoma from the middle Black Sea region of Turkey.MethodsWe retrospectively reviewed the records of 64 consecutive patients with locally advanced cervix uteri carcinoma who were treated from January 2013 to 2016 in our radiation oncology department. All patients staging and radiotherapy planning were performed with modern imaging techniques including magnetic resonance imaging and positron-emission-tomography/computed tomography before radical radiotherapy. Thereafter, all of them were treated with external beam radiotherapy and concurrent cis-platinum-based chemotherapy followed by three-dimensional intra-cavitary high-dose-rate brachytherapy.ResultsThe median age at diagnosis was 54.5 years. The median follow-up period was 21 months. Acute grade 3 toxicity was detected in 3.1% of patients. Late toxicity was not detected in any patient. The 1- and 3-year progression-free survival rates were 83.6 and 67.5%, respectively. The 1- and 3-year overall survival rates were 95.7 and 76.9%, respectively. The most important prognostic factor was the FIGO stage. Distant metastasis was the most common cause of death in patients with locally advanced cervix uteri carcinoma despite radical radiotherapy.ConclusionsIn patients with locally-advanced cervix uteri carcinoma from the middle Black Sea region of our developing country, acceptable toxicity and survival rates are achieved similar to the recent literature from developed countries with using of modern staging, planning and radical radiotherapy techniques. However, recurrence was mostly in the form of distant metastases and further investigations on systemic therapies are required.

show abstract

“…The use of carboplatin is supported by small phase I and II studies and pre-clinical evidence of synergism of this drug with RT [75]. A meta-analysis of 12 studies and 1698 patients suggested poorer complete response (OR 0.53; 95% CI 0.34-0.82) and a trend toward inferior survival (3-year OS = OR 0.70; 95% CI 0.46-1.05) with weekly carboplatin [76].…”

Section: Place Of Carboplatinmentioning

confidence: 99%

Optimal treatment in locally advanced cervical cancer

Gennigens

Cuypere

Hermesse

et al. 2021

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Introduction: Locally advanced cervical cancer (LACC) (International Federation of Gynecology and Obstetrics (FIGO) 2009/2018 -stages IB2-IVA/IB3-IVA, respectively) is treated using a multimodal approach that includes chemoradiotherapy followed by brachytherapy.Areas covered: This review provides an overview of the progress made over the past decade in the treatment of LACC. Prognostic factors, FIGO classification and the role of imaging staging will be discussed. Efficacy of external-beam radiotherapy, brachytherapy and chemotherapy will be detailed. Indications for para-aortic staging lymphadenectomy and adjuvant hysterectomy, as well as follow-up and special population, will be covered. Expert opinion:The initial workup is one of the most crucial steps in the optimal care of patients, which should be realized by a multidisciplinary expert team. With the implementation of modern conformal radiotherapy techniques, the local control rate has been optimized. Nevertheless, 40% of patients experience recurrence with distant metastasis and a dismal prognosis. Currently, a clear benefit of neo-and adjuvant chemotherapy has not been established. The future likely involves (1) improved selection of patients for whom treatment intensification is justified, (2) a combination of new drugs with chemoradiation that are currently being tested in trials, and (3) the development of tailored treatment based on molecular characteristics.

show abstract

The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: A meta-analysis

Cited by 21 publications

References 35 publications

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma

Radical radiotherapy in patients with cervix uteri carcinoma: experience of Ondokuz Mayis University

Optimal treatment in locally advanced cervical cancer

Contact Info

Product

Resources

About